Seòmar agus comataidhean

Public Health Scotland (PHS) uses the national waiting times warehouse to collect electronic patient records covering the waits that patients experience waiting for treatment as an inpatient or day case under the Treatment Time Guarantee. This data source can be used routinely to identify the specialty of treatment. However this information does not provide the level of detail requested.

More detailed information on the procedure(s) that is planned or undertaken for a patient will be held locally by NHS Boards.

Statistics relating to the waits patients experience for inpatient or day case treatment at specialty level are published up to 31 March 2022 and can be found using the link below:

https://publichealthscotland.scot/media/13252/ipdc_may22.xlsx

To date our commitment to provide long-term investment of over £500 million on bus priority infrastructure has taken the form of the Bus Partnership Fund (BPF) and the Bus Priority Rapid Deployment Fund (BPRDF). Both funds aim to support local authorities – in partnership with bus operators – to tackle the negative impacts of congestion on bus services.

In March 2020, the BPF was paused as a result of the COVID-19 pandemic. The BPRDF provided funding to local authorities to deliver temporary bus priority measures during the pandemic. The BPF relaunched in November 2020 for proposals for permanent priority measures on local roads. Through BPF, an initial £25.8m of funding has been awarded to eleven partnerships covering 28 local authorities for initial appraisal work to develop ambitious new bus priority infrastructure.

We welcome Leukaemia Care’s report and its recommendations to improve patient outcomes. We are pleased to say that we are closely aligned to the recommendations found in this report. Our Scottish Referral Guidelines for Suspected Cancer, published in January 2019, ensure patients on active monitoring are accounted for in planning cancer care and support primary care clinicians in recognising cancer symptoms, including chronic lymphocytic leukaemia.

We continue to work with health professionals and the Scottish Primary Care Cancer Group to raise awareness of symptoms and promote referral best practice.

Alongside this work, funding of up to £2.5 million has been issued over 2021-22 and 2022-23 to support 12 pilot programmes across Scotland to deliver a single point of contact (SPoC) for cancer patients. This contact will support patients to discuss questions or anxieties related to their clinical care from the point of diagnosis, receive timely and accurate advice on their appointments, test and results, have the chance to discuss what non-clinical support may be available for them and their family following a cancer diagnosis, understand their treatment plan and expected timelines for treatment delivery, self-manage (aspects of) their condition, and access available services as appropriate following discharge.

Additionally, we have worked with the Scottish Cancer Coalition (SCC) to produce a patient leaflet to highlight the work of the charities which are members of the coalition and the support they can provide to patients.

It is not possible to undertake an assessment of the impact on emissions from road vehicles as a direct result of the reduced ScotRail timetable. There is not specific data available on any change in road vehicle kilometres that could be attributed to reduced rail services.

Transport trends data since 16 May 2022 show a fall in rail travel of 14% and an increase in concessionary bus patronage and car use, both by 1% in the same period.

Most Health Boards across NHS Scotland offer fast-track clinics for patients with an urgent suspicion of skin cancer, including malignant melanoma. We are supportive of coordinating tests where possible to support faster diagnosis and improve patient experience, which is why we are developing national optimal cancer diagnostic pathways.

£10 million was released in 21-22 to support the recovery and redesign of cancer pathways, including to support one-stop clinics, with similar levels of investment expected this year.

Meanwhile, we continue to support the Dermatology Consortium that are exploring solutions for the rapid diagnosis of skin cancer in NHS Scotland.

The specification of, and recruitment to staff roles supported by investment through the long COVID Support Fund is a matter for individual NHS Boards.

The Strategic Network for long COVID managed by NHS National Services Scotland is providing support to NHS Boards as they plan and implement service developments.

We are supporting NHS Boards to test the introduction of models of care that will generate learning and benefit the management of other long-term and complex conditions, including Myalgic Encephalomyelitis (ME).

I refer the member to the answer to question S6W-08992 on 17 June 2022. All answers to written Parliamentary Questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

I refer the member to the answer to question S6W-06836 on 8 March 2022. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

The Scottish Government is currently working with Public Health Scotland to develop an online platform for members of the public to access information on the average waiting times for a range of treatments within their health board area. We expect the platform to be available this summer.

During the pandemic, the private sector was utilised to provide additional capacity to treat urgent and cancer patients, and this proved to be of great assistance. We remain open to the option of utilising the private sector again to support orthopaedics and other specialties with excessively long waiting lists. However, at present - and for the foreseeable future - the private sector has very limited capacity due to a backlog in their own private patients. There is therefore very limited capacity available for the treatment of NHS patients in these facilities.